Circle Pharma, Inc., a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, appointed Michael Cox, senior vice president, head of early development, and Edward Garmey, consulting chief medical officer. The additions to the leadership team further bolster Circle Pharma’s capabilities in oncology drug development as it advances its Cyclin A/B inhibitor program into clinical studies.

Cox will play a crucial role in driving the company’s clinical development, providing strategic leadership, and overseeing the execution of early-stage clinical programs. He has held key leadership positions in oncology drug development, including serving as vice president, clinical development at Day One Biopharmaceuticals, Inc., where he successfully led global oncology programs across all stages of development. Previously, Cox was the executive director of pediatric clinical development and medical affairs at Loxo Oncology Inc. and contributed to the development of multiple oncology assets. Earlier in his career, he held roles at Bayer Healthcare AG, Merck KGaA, and Amgen.

Garmey will provide clinical strategy leadership and medical expertise, guiding the clinical development of the company’s pipeline programs and fostering partnerships with key stakeholders. Garmey is a highly regarded former academic hematologist-oncologist with over 17 years of experience in the biopharmaceutical industry. He has served as chief medical officer and senior vice president at Cerulean Pharma, where he led the initiation of multi-national clinical trials for multiple drug programs and played a key role in the company’s successful IPO. Earlier in his career, he was the vice president of clinical development at ArQule.

“We are thrilled to welcome Michael and Edward to Circle Pharma,” said David Earp, President and CEO of Circle Pharma. “Their exceptional backgrounds and deep expertise in clinical development and medical affairs will be instrumental in accelerating our efforts to develop groundbreaking oncology therapeutics. We look forward to their contributions as we advance our lead program into the clinic and continue to drive innovation in cancer treatment. We are in a period of dynamic growth as we prepare to advance our Cyclin A/B inhibitor into clinical studies. With the leadership and expertise of Michael and Edward, the company is well-positioned to bring its transformative macrocycle therapeutics to patients.”